Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Trastuzumab and Hyaluronidase-oysk

Placeholder slot
 (tras-TOO-zoo-mab … HY-al-yoo-RAH-nih-days)

Trastuzumab and hyaluronidase-oysk consists of a combination of the monoclonal antibody trastuzumab and a recombinant enzyme called hyaluronidase-oysk, which allows trastuzumab to more easily enter tissues. Trastuzumab binds to HER2, a protein found in high levels on some cancer cells and causes them to grow. This binding blocks the ability of HER2-positive cancer cells to send chemical signals that tell them to grow. It also stimulates the immune system to kill cells that have a lot of HER2. Trastuzumab and hyaluronidase-oysk is a type of targeted therapy drug.

US Brand Name(s)
Herceptin Hylecta
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Trastuzumab and hyaluronidase-oysk is approved to treat:

Trastuzumab and hyaluronidase-oysk is a form of trastuzumab that is given as a subcutaneous injection. This form can be given in less time than trastuzumab, which is given as an infusion. For more information about trastuzumab that may apply to trastuzumab and hyaluronidase-oysk, see the Drug Information Summary for Trastuzumab.

More About Trastuzumab and Hyaluronidase-oysk

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Trastuzumab and Hyaluronidase-oysk - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Trastuzumab And Hyaluronidase-oysk - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email